190 related articles for article (PubMed ID: 7600540)
1. Mode of action-based risk assessment of genotoxic carcinogens.
Hartwig A; Arand M; Epe B; Guth S; Jahnke G; Lampen A; Martus HJ; Monien B; Rietjens IMCM; Schmitz-Spanke S; Schriever-Schwemmer G; Steinberg P; Eisenbrand G
Arch Toxicol; 2020 Jun; 94(6):1787-1877. PubMed ID: 32542409
[TBL] [Abstract][Full Text] [Related]
2. Chemical carcinogen safety testing: OECD expert group international consensus on the development of an integrated approach for the testing and assessment of chemical non-genotoxic carcinogens.
Jacobs MN; Colacci A; Corvi R; Vaccari M; Aguila MC; Corvaro M; Delrue N; Desaulniers D; Ertych N; Jacobs A; Luijten M; Madia F; Nishikawa A; Ogawa K; Ohmori K; Paparella M; Sharma AK; Vasseur P
Arch Toxicol; 2020 Aug; 94(8):2899-2923. PubMed ID: 32594184
[TBL] [Abstract][Full Text] [Related]
3. Conflicting views on chemical carcinogenesis arising from the design and evaluation of rodent carcinogenicity studies.
Melnick RL; Thayer KA; Bucher JR
Environ Health Perspect; 2008 Jan; 116(1):130-5. PubMed ID: 18197312
[TBL] [Abstract][Full Text] [Related]
4.
Keller DA; Bassan A; Amberg A; Burns Naas LA; Chambers J; Cross K; Hall F; Jahnke GD; Luniwal A; Manganelli S; Mestres J; Mihalchik-Burhans AL; Woolley D; Tice RR
Front Toxicol; 2023; 5():1234498. PubMed ID: 38026843
[No Abstract] [Full Text] [Related]
5. What is the meaning of 'A compound is carcinogenic'?
Schrenk D
Toxicol Rep; 2018; 5():504-511. PubMed ID: 29854622
[TBL] [Abstract][Full Text] [Related]
6. Application of key events analysis to chemical carcinogens and noncarcinogens.
Boobis AR; Daston GP; Preston RJ; Olin SS
Crit Rev Food Sci Nutr; 2009 Sep; 49(8):690-707. PubMed ID: 19690995
[TBL] [Abstract][Full Text] [Related]
7. Does GLP enhance the quality of toxicological evidence for regulatory decisions?
Borgert CJ; Becker RA; Carlton BD; Hanson M; Kwiatkowski PL; Sue Marty M; McCarty LS; Quill TF; Solomon K; Van Der Kraak G; Witorsch RJ; Yi KD
Toxicol Sci; 2016 Jun; 151(2):206-13. PubMed ID: 27208076
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and Carcinogenicity of Dichlorodiphenyltrichloroethane (DDT).
Harada T; Takeda M; Kojima S; Tomiyama N
Toxicol Res; 2016 Jan; 32(1):21-33. PubMed ID: 26977256
[TBL] [Abstract][Full Text] [Related]
9. Successful drug development despite adverse preclinical findings part 1: processes to address issues and most important findings.
Ettlin RA; Kuroda J; Plassmann S; Prentice DE
J Toxicol Pathol; 2010 Dec; 23(4):189-211. PubMed ID: 22272031
[TBL] [Abstract][Full Text] [Related]
10. Effect of vitamin E on hepatic cell proliferation and apoptosis in mice deficient in the p50 subunit of NF-κB after treatment with phenobarbital.
Li J; Harp C; Tharappel JC; Spear BT; Glauert HP
Food Chem Toxicol; 2011 Oct; 49(10):2706-9. PubMed ID: 21726593
[TBL] [Abstract][Full Text] [Related]
11. Effect of phenobarbital on hepatic cell proliferation and apoptosis in mice deficient in the p50 subunit of NF-kappaB.
Tharappel JC; Spear BT; Glauert HP
Toxicol Appl Pharmacol; 2008 Feb; 226(3):338-44. PubMed ID: 17963809
[TBL] [Abstract][Full Text] [Related]
12. An autoradiographic study of cellular proliferaton, DNA synthesis and cell cycle variability in the rat liver caused by phenobarbital-induced oxidative stress: the protective role of melatonin.
El-Sokkary GH
Cell Mol Biol Lett; 2007 Sep; 12(3):317-30. PubMed ID: 17297560
[TBL] [Abstract][Full Text] [Related]
13. Use of mechanistic data in assessing human risks from exposure to particles.
McClellan RO
Environ Health Perspect; 1997 Sep; 105 Suppl 5(Suppl 5):1363-72. PubMed ID: 9400751
[TBL] [Abstract][Full Text] [Related]
14. The significance of mouse liver tumor formation for carcinogenic risk assessment: results and conclusions from a survey of ten years of testing by the agrochemical industry.
Carmichael NG; Enzmann H; Pate I; Waechter F
Environ Health Perspect; 1997 Nov; 105(11):1196-203. PubMed ID: 9370513
[TBL] [Abstract][Full Text] [Related]
15. A strategy for establishing mode of action of chemical carcinogens as a guide for approaches to risk assessments.
Butterworth BE; Conolly RB; Morgan KT
Cancer Lett; 1995 Jun; 93(1):129-46. PubMed ID: 7600540
[TBL] [Abstract][Full Text] [Related]
16. Chloroform mode of action: implications for cancer risk assessment.
Golden RJ; Holm SE; Robinson DE; Julkunen PH; Reese EA
Regul Toxicol Pharmacol; 1997 Oct; 26(2):142-55. PubMed ID: 9356278
[TBL] [Abstract][Full Text] [Related]
17. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
Gaylor DW
Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
[TBL] [Abstract][Full Text] [Related]
18. A decision tree approach for carcinogen risk assessment.
Butterworth BE; Eldridge SR
Prog Clin Biol Res; 1995; 391():49-70. PubMed ID: 8532737
[TBL] [Abstract][Full Text] [Related]
19. A classification framework and practical guidance for establishing a mode of action for chemical carcinogens.
Butterworth BE
Regul Toxicol Pharmacol; 2006 Jun; 45(1):9-23. PubMed ID: 16530901
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
